A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study to evaluate the safety of weekly SC administration
of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening
period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit
2 weeks after the last treatment.